Expert rules in antimicrobial susceptibility testing: State of the art
|
|
- Bertina Carroll
- 5 years ago
- Views:
Transcription
1 Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Dr. Rafael Cantón Dpto. de Microbiología Universidad Complutense Madrid. Spain
2 Antimicrobial susceptibility testing Clinical categorization (S, I, R) Intrepretive reading Application of expert rules Based on clinical breakpoints Based on resistance mechanisms knowledge Based both on clinical evidence and resistance mechanisms knowledge
3 ANTIBIOGRAM: CLINICAL CATEGORIZATION CLSI (NCCLS) CLINICAL BREAKPOINTS EUCAST CLINICAL BREAKPOINTS EPIDEMIOLOGYCAL CUT-OFF
4 Cefalosporins Antibiogram clinical categorization Enterobacteriaceae and extended spectrum cephalosporins CLSI EUCAST S ( ) R ( ) S ( ) R (>) ECOFF ( ) Cefotaxime (E. coli) (K. pneumoniae) Ceftazidime Cefepime M100S19, CLSI 2009 M100S20, CLSI Version 1.0 Dec Version 1.1 Apr-2010
5 Interpretive reading of in-vitro antimicrobial test results 1.- To establish the susceptibility phenotype 2.- To infer the potential resistance mechanism 3.- To predict previously defined phenotype from the resistance mechanism Patrice Courvalin, ASM News, 1992
6 Antimicrobial Antibiogram interpretative reading Importance of bacterial identification MIC (mg/l) Ampicillin >64 Amox/clav >32/16 Ticarcillin >64 Piperacillin 32 Piper/Tazo 16/4 Cefuroxime >64 Cefoxitin >32 Cefotaxime 4 Ceftazidime 8 Cefepime 1 Organisms Potential phenoype E. coli AmpC hyperproduction plasmid AmpC ESBL + porin deficiency K. pneumoniae ESBL + porin deficiency E. cloacae ESBL
7 Antibiogram interpretative reading: the classical example Escherichia coli and ESBL
8 Stenotrophomonas maltophilia (L1+ L2 enzymes) CTX CPM AMC CAZ ATM
9 ATM CTX AMC AMP CAZ ATM CTX AMC AMP CAZ
10 Proteus vulgaris hiperproduction of chromosomal b-lactamase (Class A) AMP PIP CEF CXM CAZ FOX CTX AMC FEP ATM Proteus vulgaris IPM Ampicillin Ticarcillin Piperacillin Piper/Tazo Amox/clav Cefalotin Cefoxitin Cefuroxime Cefotaxime Ceftazidime Cefepime Imipenem MIC >256 8->256 8-> > > ,12-0,5 0,5-2 0,5-2 Interp. R R S/R S/R S/I R S R R S S/I S
11 CTX-30 µg AMC (20:10 µg) CTX+CLAV µg CLAV -10 µg CTX-30 µg CTX CTX+CLAV-4 µg
12 Integration of intepretive reading in a clinical microbiology lab Microorganism To indentify clinical transcendence of the resistance phenotype Identification + antibiogram Phenotype characterization Infer of the resistance mechanism Refining susceptibility clinical interpretation Deduction of susceptibility of non-tested antibiotics Interpretation of antibiogram (S/I/R) Report of the results R. Cantón. Enferm Infecc Microbiol Clin 2002; 20: R. Cantón. Enferm Infecc Microbiol Clin 2008; 28:375-85
13 EUCAST expert rules An expert rule... Description of action to be taken, based on current clinical and/or microbiological evidence, in response to specific antimicrobial susceptibility test results Assist clinical microbiologists in the interpretation of antimicrobial susceptibility tests Contribute to quality assurance by highlighting anomalous or unlikely results
14 EUCAST expert rules A classical example... S. aureus resistant to oxacillin or cefoxitin Acquisition of the meca gene Report resistant to all β-lactams!
15 EUCAST expert rules A classical example... P E OX CN AK Rule 12.3 (version 2) IF resistant to gentamicin, THEN report as resistant to all aminoglycosides* *Resistance to tobramycin is generally due to the production of ANT(4 )(4 )I or bifunctional APH(2 )-AAC(6) enzymes that determine loss of synergism of kanamycin, tobramycin and amikacin with β-lactams and glycopeptides irrespective of MIC values.
16 EUCAST expert rules The EUCAST expert rules in antimicrobial susceptibility testing are divided into: - intrinsic resistances - exceptional phenotypes - interpretive rules
17 EUCAST expert rules Intrinsic resistance Opposed to acquired or mutional resistance Characteristic of all (or almost all) representatives of the species The antimicrobial activity of the drug is clinically insufficient or antimicrobial resistance innate as to render it clinically useless Antimicrobial susceptibility testing is normally unnecessary In these species, susceptible results should be viewed with caution (this indicates an error in identification or susceptibility testing) - if S is confirmed the drug should preferably not be used - R may be expressed at a low level (MIC close to the S breakpoint) although the antibiotic is not considered clinically active
18 Ampicillin Amoxicilinclavulanate Ticarcillin Piperacillin Cefazolin Cefoxitin Cefamandole Cefuroxime Aminoglycosides Tetracyclines/ tigecycline Polymyxin B/ Colistin Nitrofurantoin Rule no. Organisms EUCAST expert rules Intrinsic resistances affecting ß-lactams 1.1 Citrobacter koseri R R R 1.2 Citrobacter freundii R R R R 1.3 Enterobacter cloacae R R R R 1.4 Enterobacter aerogenes R R R R 1.5 Escherichia hermannii R R R 1.6 Hafnia alvei R R R 1.7 Klebsiella spp. R R 1.8 Morganella morganii R R R R R R R 1.9 Proteus mirabilis R R R 1.10 Proteus vulgaris R R R R R R R 1.11 Proteus penneri R R R R R R R 1.12 Providencia rettgeri R R R Note 2 R R R 1.13 Providencia stuartii R R R R R R 1.14 Serratia marcescens R R R R R Note 3 R R 1.15 Yersinia enterocolitica R R R R R R R 1.16 Yersinia pseudotuberculosis R
19 EUCAST expert rules Exceptional phenotypes Resistances of some bacterial species to particular antimicrobial agents which have not yet been reported or are very rare They should be checked as they may also indicate an error in identification or susceptibility testing. If they are confirmed locally: - the isolate should be further studied - sent to a reference laboratory for independent confirmation The may change with time as resistance may develop and increase over time There may also be local or national differences. Very rare in one hospital, area or country, may be more common in another
20 .. Rule no. EUCAST expert rules Organisms Exceptional phenotypes Excepcional phenotype 5.1 Any Enterobacteriaceae Resistant to ertapenem, meropenem, imipenem (except Proteus spp.) 5.2 P. aeruginosa, Acinetobacter spp. Resistant to colistin 5.3 Haemophilus influenzae Resistant to any 3 rd -gen. cephalosporin, carbapenems, fluoroquinolones 5.4 Moraxella catarrhalis Resistant to ciprofloxacin, any 3 rd -gen. cephalosporin 5.5 Neisseria meningitidis Resistant to penicillin (MIC>1 mg/l), 3 rd -gen. cephalosporins, ciprofloxacin 5.6 Neisseria gonorrhoeae Resistant to 3 rd -gen. cephalosporins, spectinomycin
21 EUCAST expert rules Interpretive rules: IF...THEN approach Simple rules - IF S. aureus is R to oxacillin or cefoxitin THEN report R to all β-lactams - IF not all carbapenems are tested, THEN test results regarding one carbapenem (imipenem, meropenem, ertapenem, doripenem) cannot be inferred to the other carbapenems. Complicated rules - IF Enterobacteriaceae I to tobramycin, R to gentamicin and S to amikacin THEN report R to tobramycin They are evidence supported, but often not conclusive with different opinions regarding the most appropriate clinical action Based on current published evidence (the quality of evidence should be assessed and exceptions to any rules should be noted)
22 EUCAST expert rules Evidences A. There is clinical evidence that reporting the test result as susceptible leads to clinical failures B. Evidence is weak and based only on a few case reports or on experimental models. It is presumed that reporting the test result as susceptible may lead to clinical failures C. There is no clinical evidence, but microbiological data suggest that clinical use of the agent should be discouraged
23 EUCAST expert rules Evidences A. There is clinical evidence that reporting the test result as susceptible leads to clinical failures
24 EUCAST expert rules Evidences B. Evidence is weak and based only on a few case reports or on experimental models. It is presumed that reporting the test result as susceptible may lead to clinical failures
25 EUCAST expert rules Evidences C. There is no clinical evidence, but microbiological data suggest that clinical use of the agent should be discouraged
26 EUCAST expert rules Interpretive rules can be modified over time...!
27 Rule No. EUCAST expert rules Interpretive rules can be modified over time... Rule Exceptions Scientific basis Grade* References 9.1* If R or I to any 3 rd or 4 th gen. oxyimino-ceph. (i.e. cefepime, cefotaxime, cefpirome, cefpodoxime, ceftazidime or ceftriaxone) or aztreonam, test for ESBL. If positive, edit the S result for any of these cephalosporins, including 4 th gen. agents and for aztreonam, to I and edit the I result to R. ESBL producers may appear susceptible to penicillin/ ß- lactamase inhibitor combinations. The use of these combinations against ESBL producers remains controversial, and should be approached with caution. If ESBL negative see rule 9.2. * Enterobacteriaceae (for Klebsiella oxytoca and Citrobacter koseri see 9.3) A few ESB producers may appear S in vitro to some 3 rd or 4 th gen. oxyiminocephalosporin or aztreonam. Efficacy of cefotaxime, ceftazidime and ceftriaxone against ESBL-producing isolates with MICs lower than 2 mg/l remains to be fully documented A. There is clinical evidence that reporting the test result as susceptible leads to clinical failures B. Evidence is weak based only on a few case reports or on experimental models. It is presumed that reporting the test as susceptible my lead to clinical failures C. There is currently no clinical evidence, but microbiological data suggest that clinical use of the agent should be discouraged C Burn-Buisson et al Jarlier V et al., Livermore DM and Brown DF, Wong- Beringer A et al., Paterson D and Bonomo R, 2005 Paterson DL et al Bhavnani SM et al. 2006
28 EUCAST expert rules 2010 Ceftazidime and cefepime R breakpoint has been reduced from >8 mg/l to >2 mg/l Cefalosporins EUCAST S ( ) R (>) Cefotaxime 1 2 Ceftazidime 1 4 Cefepime 1 4 Report as found regardless of the presence of a resistance mechanism (ESBL or other)
29 EUCAST expert rules EUCAST expert rules should be applied with EUCAST breakpoints!...
30 3 rd & 4 th gen. cephalosporin breakpoints in Enterobacteriaceae CLSI (2010) EUCAST (2010) Cefalosporins S R S R Cefotaxime >2 Ceftriaxone >2 Ceftazidime >4 Cefepime >4 Aztreonam >4 Remember! R category is in CLSI while > in EUCAST = =
31 Cephalosporin breakpoints in Enterobacteriaceae Current EUCAST approach is aimed - To provide breakpoints consistent with new Pk/Pd knowledge - To balance the clinical significance of ESBL resistance mechanism - To relate MIC values to clinical response (nevertheless more clinical evidence are still needed!) - To avoid the delay of reporting for ESBL-producing organisms
32 Cephalosporin breakpoints in Enterobacteriaceae E. coli with reduced susceptibility to 3 rd & 4 th gen. cephalosporins Antibiotic MIC (mg/l) CLSI EUCAST Amoxicillin >16 R R R R Amox/clav 4/2 a ; 8/2 b S S S S Cefazolin >32 R R R R Cefoxitin 4 S R S NA c NA c Ceftotaxime >16 R R R R Ceftazidime 4 S R S I R I Cefepime 2 S R S I R I Aztreonam 4 S R S I R I Imipenem 0.25 S S S S Meropenem 0.03 S S S S a CLSI: 2:1 ratio; b EUCAST: fixed concentration (2 mg/l); c NA: not available
33 Cephalosporin breakpoints in Enterobacteriaceae The murine thigh infection model showed that the % T>CMI was similar in therapy (3 rd /4 th gen. cephalosporins) against ESBL and non-esbl groups - PK/PD breakpoints should be independent of the resistance mechanisms - The MIC of ß-lactam in an ESBL-producing isolate can be used to predict likely human outcomes from PK/PD models Andes & Craig. Clin Microbiol Infect 2005; 11 (Supp. 6): 10-7
34 % of clinical failure cephalosporin treat Cephalosporin breakpoints in Enterobacteriaceae Clinical outcome of 3 er /4 th gen. cephalosporins treatment in patients with serious infections due to ESBL-organisms % of clinical failure with cephalosporin treatment < MIC MIC (mg/l), 3rd of 3/ rd 4th /4 gen. cephalosporins Paterson et al. J Clin Microbiol 2001; 39:
35 % of success Cephalosporin breakpoints in Enterobacteriaceae Clinical outcome in 42 patients with ESBL-producing Klebsiella spp. or E. coli bacteraemia and treated with cephalosporin monotherapy CMI (mg/l) Andes & Craig. Clin Microbiol Infect 2005; 11 (Supp. 6): 10-7
36 Cephalosporin breakpoints in Enterobacteriaceae The EUCAST approach Cefotaxime and ceftriaxone breakpoints: S 1 / R >2 mg/l - consistent with Pk/Pd breakpoints - clinical data: outcome is poor when MICs are >2 mg/l no differences with non-esbl producers with MICs 1 mg/l S R MacGowan A. Clin Microbiol Infect 2008; 14 (Suppl 1):166-8
37 Cephalosporin breakpoints in Enterobacteriaceae The EUCAST approach Ceftazidime, cefepime, aztreonam: S 1 / R > 4 mg/l - Pk/Pd: - probability of target attainment (PTA), ft/mic = 60% - Clinical data: - with doses of 1 g x 3, PTA is achieved for MICs of 4 mg/l S 2 g x 3, PTA is achieved for MICs of 8 mg/l R - no differences with non-esbl producers with MICs 1 mg/l - the S breakpoint was reduced from 4 to 1 mg/l due to uncertain reports of clinical outcome for isolates with MICs 2-4 mg/l - outcome decrease with MICs >4 mg/l R breakpoint
38 Cephalosporin breakpoints in Enterobacteriaceae When using the new EUCAST breakpoints. - it is no longer necessary to edit results for cephalosporins or aztreonam from susceptible to resistant (report as found ) NO CLINICAL CATEGORIZATION MODIFICATION IS NEEDED - ESBL testing is no longer necessary before reporting the results, but still be useful for epidemiological or infection control purposes NO ESBL CONFIRMATION IS NEED UNLESS FOR EPIDEMIOLOGY
39
40
41 Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Dr. Rafael Cantón Dpto. de Microbiología Universidad Complutense Madrid. Spain
ESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationUniversity of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationClinical Microbiology Newsletter
Clinical Microbiology Newsletter $88 Vol. 30, No. 10 www.cmnewsletter.com May 15, 2008 Newer β-lactamases: Clinical and Laboratory Implications, Part I * Ellen Smith Moland, B.S.M.T., Soo-Young Kim, M.D.,
More informationEUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator
EUCAST Frequently Asked Questions Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator Erika Matuschek EUCAST Development Laboratory, Växjö Sweden Monday 24
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More informationThis material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.
Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital and Stollery Children's Hospital Antibiogram 2006 This material is supported in part by unrestricted
More informationbreakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1):
REVIEW Breakpoints for intravenously used cephalosporins in Enterobacteriaceae EUCAST and CLSI breakpoints G. Kahlmeter Department of Clinical Microbiology, Central Hospital, Växjö, Sweden ABSTRACT It
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationWhat is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden
What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationDisclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program
47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax
More informationPhenotypic detection of ESBLs and carbapenemases
Phenotypic detection of ESBLs and carbapenemases Standardized susceptibility testing residential workshop 2016 Katie Hopkins PhD Clinical Scientist Antimicrobial Resistance and Healthcare Associated Infections
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationHUSRES Annual Report 2009 Martti Vaara
HUSRES Annual Report 2009 Martti Vaara www.huslab.fi www.intra.hus.fi Martti Vaara, 2/2010 1 The basis of this HUSRES 2009 report is the HUSLAB/Whonet database 2009, which contains susceptibility data
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationTranslocation Studies Mid-Term Review (MTR) Meeting Marseille, France
Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationNew Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection
New Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection Stephen G. Jenkins, PhD, F(AAM), D(ABMM) Professor of Pathology and Laboratory Medicine Professor of Pathology in Medicine
More informationClinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes
56 Clinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes Patrick N. A. Harris, BSc, MBBS, MRCP, DTM&H, FRACP, FRCPA 1 1 Infection and
More informationMechanisms of resistance to ceftolozane tazobactam Antonio Oliver Servicio de Microbiología, Hospital Son Espases.
Mechanisms of resistance to ceftolozane tazobactam Antonio Oliver Servicio de Microbiología, Hospital Son Espases. Palma de Mallorca SPAIN ECCMID 2018. Madrid, April 22 nd Disclosures: Awarded research
More informationReceived 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1965 1969 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00203-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparative
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationCARBAPENEMASE PRODUCING ENTEROBACTERIACEAE
CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE Veroniek Saegeman Veroniek Saegeman UZLeuven Carbapenemase producing Enterobacteriaceae (CPE) Introduction on antibiotic resistance Classification of ß-lactamases
More informationAgainst Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationAntimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2005, p. 3501 3512 Vol. 49, No. 8 0066-4804/05/$08.00 0 doi:10.1128/aac.49.8.3501 3512.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More information(DHA-1): Microbiologic and Clinical Implications
AAC Accepts, published online ahead of print on 20 September 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00083-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationMIC Test Strip for antimicrobial susceptibility testing
for antimicrobial susceptibility testing Liofilchem Liofilchem Quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) is a quantitative assay for determining the Minimum Inhibitory
More informationDevelopment of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s
Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationSusceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)
b r a z j i n f e c t d i s. 2 0 1 3;1 7(6):672 681 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original article Susceptibility rates in Latin American nations: report from
More information(and breakpoint table, MIC and. by author. ESCMID Online Lecture Library. conventions) ECCMID 2011, Milan
EUCAST definitions (and breakpoint table, MIC and zone distribution ib ti website ECCMID 2011, Milan conventions) Derek Brown Clinically susceptible/resistant A microorganism is defined as susceptible
More informationST11 KPC-2 Klebsiella pneumoniae detected in Taiwan
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05576-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 183 190 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.183 190.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Contemporary
More informationAntibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:
Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Michael Satlin, MD, MS Assistant Professor of Medicine Division of Infectious Diseases Weill Cornell Medicine March 4, 2016 1 Disclosures
More informationCarbapenems and Enterobacteriaceae
Title Carbapenems and Enterobacteriaceae Presenter s details NHLS Dr Khine Swe Swe/Han FC Path ( Micro), SA MMed( micro), SA DTMH(Wits univ),sa PDIC(Stellen univ)sa MB,BS(Yangon),Myanmar Pathologist,Consultant/Lecturer,
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationHigh diversity of extended-spectrum b-lactamases among clinical isolates of Enterobacteriaceae from Portugal
Journal of Antimicrobial Chemotherapy Advance Access published October 3, 2007 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkm381 High diversity of extended-spectrum b-lactamases among clinical
More informationAuthor: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents
t Title: In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 Author: Souha Kanj Andrew Whitelaw
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationDetecting CRE. what does one need to do?
5 th ICAN Conference, Harare 4 th November 2014 Room 2: 10:30-12:00 Detecting CRE (Carbapenem-resistant Enterobacteriaceae) what does one need to do? Dr Nizam Damani Associate Medical Director Infection
More informationAbstract. a Jann-Tay Wang 1, Un-In Wu 2, Tsai-Ling Yang Lauderdale 3, Mei-Chen Chen 3, Shu-Ying Li 4, Le-Yin Hsu 5, Shan-Chwen Chang 1,6 *
RESEARCH ARTICLE Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan Jann-Tay Wang 1, Un-In Wu 2, Tsai-Ling Yang Lauderdale 3, Mei-Chen Chen 3, Shu-Ying Li 4, Le-Yin Hsu 5, Shan-Chwen Chang 1,6 * 1
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationResults and experience of BARN ESBL project. Marina Ivanova and project team Tallinn
Results and experience of BARN ESBL project Marina Ivanova and project team Tallinn 13.05.2013 Aim of the project Improvement of detection and surveillance of resistance caused by extended spectrum betalactamase
More informationRapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann
Rapid identification of emerging resistance in Gram negatives Prof. Patrice Nordmann Emerging Resistance threats, CDC USA-2013 Enterobacteriaceae producing extendedspectrum β-lactamases (ESBL) Multi-resistant
More informationCarbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan An Infection Control Emergency Speaker: L Kristopher Siu Principal Investigator Division of Infectious Diseases National Institute
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationAMPC BETA LACTAMASES AMONG GRAM NEGATIVE CLINICAL ISOLATES FROM A TERTIARY HOSPITAL, SOUTH INDIA. Mohamudha Parveen R., Harish B.N., Parija S.C.
Brazilian Journal of Microbiology (2010) 41: 596-602 ISSN 1517-8382 AMPC BETA LACTAMASES AMONG GRAM NEGATIVE CLINICAL ISOLATES FROM A TERTIARY HOSPITAL, SOUTH INDIA Mohamudha Parveen R., Harish B.N., Parija
More informationMulticenter study of the prevalence and the resistance mechanisms of carbapenem-resistant Enterobacteriaceae (CPE) in Belgium in
Multicenter study of the prevalence and the resistance mechanisms of carbapenem-resistant Enterobacteriaceae (CPE) in Belgium in 2011-2012 Study conducted by: 1. National Reference Center (NRC) for ESBL-producing
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationDoripenem: pharmacokinetics and pharmacodynamics. Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD
16/04/2009 1 Doripenem: pharmacokinetics and pharmacodynamics Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD Unité de Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute
More informationPrevalence of acquired AmpC b-lactamases in Enterobacteriaceae lacking inducible chromosomal ampc genes at a Spanish hospital from 1999 to 2007
472 Clinical Microbiology and Infection, Volume 16 Number 5, May 2010 CMI 4. Swidsinski A, Mendling W, Loening-Baucke V et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005; 106: 1013 1023.
More information(Plasmid mediated) Carbapenemases. Timothy R. Walsh, Cardiff University, Wales
(Plasmid mediated) Carbapenemases Timothy R. Walsh, Cardiff University, Wales What is a carbapenemase? How much carbapenem do they need to breakdown before they are called a carbapenemase? ESBL-enzymes
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationJournal of Infectious Diseases and
Journal of Infectious Diseases & Therapy ISSN: 2332-0877 Journal of Infectious Diseases and Therapy Santanirand et al., J Infect Dis Ther 2018, 6:5 DOI: 10.4172/2332-0877.1000378 Research Article Open
More informationUrinary Tract Infection and Pattern of Antibiotic Sensitivity in Hospitalized Patients with Diabetes Mellitus in Myanmar
Volume 2 Issue 1 2018 Page 147 to 153 Research Article Archives of Endocrinology and Diabetes Care Urinary Tract Infection and Pattern of Antibiotic Sensitivity in Hospitalized Patients with Diabetes Mellitus
More informationEmergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH
Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.
More informationTigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
Diagnostic Microbiology and Infectious Disease 52 (2005) 181 186 www.elsevier.com/locate/diagmicrobio Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
More informationFirst description of KPC-2-producing Pseudomonas putida in Brazil. Anna C. S. Almeida, Marinalda A. Vilela*, Felipe L.S. Cavalcanti, Willames M.B.S.
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05268-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 First description
More informationOther antimicrobials of interest in the era of extended-spectrum b-lactamases: fosfomycin, nitrofurantoin and tigecycline
REVIEW Other antimicrobials of interest in the era of extended-spectrum b-lactamases: fosfomycin, nitrofurantoin and tigecycline J. Garau Department of Medicine, Hospital Mutua de Terrassa, University
More informationIn Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria
In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria Warunee Punpanich MD*, Worraporn Tantichattanon MD**, Siriporn Wongwatcharapaiboon MD**, Vipa Treeratweeraphong BSc, MSc***
More informationDetecting carbapenemases in Enterobacteriaceae
Detecting carbapenemases in Enterobacteriaceae David Livermore Health Protection Agency, Colindale, London 12 August 2003 Mechanisms of carbapenem R in Enterobacteria Impermeability + AmpC or ESBL Metallo
More informationPerformance of chromid ESBL, a chromogenic medium for detection of Enterobacteriaceae producing extended-spectrum b-lactamases
Journal of Medical Microbiology (2008), 57, 310 315 DOI 10.1099/jmm.0.47625-0 Performance of chromid ESBL, a chromogenic medium for detection of Enterobacteriaceae producing extended-spectrum b-lactamases
More informationAntimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin
Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin Matthew E. Falagas, Sofia Maraki, Drosos E. Karageorgopoulos, Antonia
More informationVeterinary and Agrochemical Research Centre
Veterinary and Agrochemical Research Centre Report on susceptibility of Salmonella serotypes in Belgium. P. Butaye Susceptibility of Salmonella strains was assessed by MIC determination using Sensititer
More informationUPDATES IN ANTIBIOTIC THERAPY OF BILIARY TRACT INFECTIONS
6 ARTICOLE ORIGINALE UPDATES IN ANTIBIOTIC THERAPY OF BILIARY TRACT INFECTIONS Cristian Balahura 1,2, Petre Iacob Calistru 1,3, Gabriel Constantinescu 1,2 1 Carol Davila University of Medicine and Pharmacy,
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More informationControversial Issues in Susceptibility Testing: Point/Counterpoint. April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM)
Controversial Issues in Susceptibility Testing: Point/Counterpoint April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM) Disclosures RMH: Funding from BD, biomerieux, Beckman-Coulter, GenMark,
More informationRecommendations for Dilution Susceptibility Testing Concentrations of the Cefoperazone-Sulbactam Combination
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1987. p. 1725-1729 0095-1137/87/091725-05$02.00/O Copyright (O 1987, American Society for Microbiology Vol. 25, No. 9 In Vitro Antimicrobial Spectrum, Occurrence
More informationRevised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in
AAC Accepts, published online ahead of print on 3 December 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01180-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More information(multidrug-resistant Pseudomonas aeruginosa; MDRP)
220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM
More informationHealthy Adult cuti Patient. Cmax (mcg/ml)(mean ± SD) 73.7 ± ± 113. Vd (L)(mean ± SD) 17.9 ± ± 12.1
Brand Name: Zemdri Generic Name: plazomicin Manufacturer: Achaogen, Inc Drug Class: aminoglycoside antibacterial Uses: 1-5 Labeled: treatment of complicated urinary tract infections (cuti), including pyelonephritis,
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationXERAVATM (eravacycline): A Novel Fluorocycline Antibacterial
XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial Matteo Bassetti, MD, PhD Infectious Diseases Division University of Udine and Santa Maria Misericordia University Hospital Udine, Italy Disclosures
More informationEVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS
Indian Journal of Medical Microbiology, (2005) 23 (2):120-124 Brief Communication EVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS S Singhal, T
More informationPREVENTIVE MEDICINE - LABORATORY
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2014 vol. 118, no. 3 PREVENTIVE MEDICINE - LABORATORY ORIGINAL PAPERS CLINICAL EPIDEMIOLOGICAL STUDY ON THE INCIDENCE OF ESCHERICHIA COLI INFECTIONS IN THE CANCER PATIENTS
More informationUse of Faropenem as an Indicator of Carbapenemase Activity
JCM Accepts, published online ahead of print on 10 April 2013 J. Clin. Microbiol. doi:10.1128/jcm.00720-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Use of Faropenem as
More informationAmpC -Lactamases. George A. Jacoby* Lahey Clinic, Burlington, Massachusetts
CLINICAL MICROBIOLOGY REVIEWS, Jan. 2009, p. 161 182 Vol. 22, No. 1 0893-8512/09/$08.00 0 doi:10.1128/cmr.00036-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. AmpC -Lactamases
More informationDiane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center
Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal
More informationAnnual Surveillance Summary: Klebsiella species Infections in the Military Health System (MHS), 2017
i Annual Surveillance Summary: Klebsiella species Infections in the Military Health System (MHS), 2017 Tej Mishra and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views expressed
More informationCAT Critically Appraised Topic
CAT Critically Appraised Topic Part I: Evaluation of Three Different Agar Media for Rapid Detection of Extended- Spectrum β-lactamase Producing Enterobacteriaceae from Clinical Screening Samples. Part
More informationEmergence of non-kpc carbapenemases: NDM and more
Emergence of non-kpc carbapenemases: NDM and more --- David Livermore Health Protection Agency, UK The first acquired carbapenemase to be recognised in gram-negative bacteria was IMP-1, a metallo-type,
More informationPhenotypic and genotypic characteristics of carbapenem resistant Enterobacteriaceae in a tertiary level reference hospital in Turkey
DOI 10.1186/s12941-016-0136-2 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Phenotypic and genotypic characteristics of carbapenem resistant Enterobacteriaceae in a tertiary level
More information